MGI gene sequencing company

Location: Home /  News Center

MGI Sequencing Platform Contributes to the Identification of Hundreds of COVID-19 Samples in Ruili

Release date:2021-07-27Writer:MGIViews:428Share

RUILI, CHINA, July 6, 2021, the authorities of Ruili in Yunnan Province, Southwest China stated in its fourth press conference on COVID-19 Control and Prevention that all the positive samples are arranged to be sequenced to trace the origin of the virus.

In response, MGI urgently deployed genetic sequencing equipment and automated sample preparation system to the frontline to support the sequencing of positive samples. Four engineers of MGI rushed to Ruili from Wuhan, Chengdu and Chongqing, and completed the installation and debugging within 48 hours to ensure the successful operation of the equipment. With the close cooperation of MGI and Yunnan Provincial Center for Disease Control and Prevention, more than 158 positive samples to date have been sequenced on MGI sequencing platform.

MGI Genetic Sequencer* and Automated Sample Preparation System

The platforms in operation include two MGI’s proprietary genetic sequencers, DNBSEQ-G400* and DNBSEQ-G50* and MGISP-100 automated sample preparation system, contributing to the effective sample preparation and gene sequencing of virus.

MGI Engineers is Commissioning the Equipment

Rapid virus genome sequencing can help identify the source of infection at the very first time and provide strong support for epidemiological investigation and virus origins tracing. Since the outbreak, MGI's small, medium, and high throughput sequencing platforms have helped China discover the new coronavirus variant of the first imported case from overseas and provided strong instrumental support for the scientific guidance and clinical control of COVID-19 pandemic nationwide and internationally.

*Unless otherwise informed, all sequencers and sequencing reagents are not available in Germany, the USA, Spain, UK, Hong Kong, Sweden, and Belgium.

Quick Contact